| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Alto Neuroscience, Inc. | Director | Stock Option (right to buy) | 1.59K | $5.04K | $3.17 | Mar 8, 2024 | Direct |
| Entrada Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 38K | Jun 1, 2025 | Direct | ||
| Candel Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 28.5K | Jun 4, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| CADL | Candel Therapeutics, Inc. | Jun 4, 2025 | 1 | $0 | 4 | Jun 6, 2025 | Director |
| CADL | Candel Therapeutics, Inc. | Jun 4, 2025 | 0 | $0 | 3 | Jun 6, 2025 | Director |
| TRDA | Entrada Therapeutics, Inc. | Jun 1, 2025 | 1 | $0 | 4 | Jun 3, 2025 | Director |
| TRDA | Entrada Therapeutics, Inc. | Jun 1, 2025 | 0 | $0 | 3 | Jun 3, 2025 | Director |
| ANRO | Alto Neuroscience, Inc. | Mar 8, 2024 | 2 | $16.2K | 4 | Mar 12, 2024 | Director |
| ANRO | Alto Neuroscience, Inc. | Mar 8, 2024 | 0 | $0 | 3 | Mar 12, 2024 | Director |